GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuno-Biological Laboratories Co Ltd (TSE:4570) » Definitions » Piotroski F-Score

Immuno-Biological Laboratories Co (TSE:4570) Piotroski F-Score : 7 (As of Apr. 06, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Immuno-Biological Laboratories Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Immuno-Biological Laboratories Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Immuno-Biological Laboratories Co's Piotroski F-Score or its related term are showing as below:

TSE:4570' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of Immuno-Biological Laboratories Co was 7. The lowest was 2. And the median was 3.


Immuno-Biological Laboratories Co Piotroski F-Score Historical Data

The historical data trend for Immuno-Biological Laboratories Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuno-Biological Laboratories Co Piotroski F-Score Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 4.00 5.00 7.00

Immuno-Biological Laboratories Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 7.00 -

Competitive Comparison of Immuno-Biological Laboratories Co's Piotroski F-Score

For the Biotechnology subindustry, Immuno-Biological Laboratories Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuno-Biological Laboratories Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Immuno-Biological Laboratories Co's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 円186.7 Mil.
Cash Flow from Operations was 円133.8 Mil.
Revenue was 円816.7 Mil.
Gross Profit was 円517.3 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was (1434.337 + 1618.582) / 2 = 円1526.4595 Mil.
Total Assets at the begining of this year (Mar23) was 円1,434.3 Mil.
Long-Term Debt & Capital Lease Obligation was 円84.6 Mil.
Total Current Assets was 円1,262.1 Mil.
Total Current Liabilities was 円257.8 Mil.
Net Income was 円-289.7 Mil.

Revenue was 円794.6 Mil.
Gross Profit was 円526.7 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was (1705.338 + 1434.337) / 2 = 円1569.8375 Mil.
Total Assets at the begining of last year (Mar22) was 円1,705.3 Mil.
Long-Term Debt & Capital Lease Obligation was 円99.1 Mil.
Total Current Assets was 円1,165.3 Mil.
Total Current Liabilities was 円252.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Immuno-Biological Laboratories Co's current Net Income (TTM) was 186.7. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Immuno-Biological Laboratories Co's current Cash Flow from Operations (TTM) was 133.8. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=186.694/1434.337
=0.13016049

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-289.731/1705.338
=-0.16989652

Immuno-Biological Laboratories Co's return on assets of this year was 0.13016049. Immuno-Biological Laboratories Co's return on assets of last year was -0.16989652. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Immuno-Biological Laboratories Co's current Net Income (TTM) was 186.7. Immuno-Biological Laboratories Co's current Cash Flow from Operations (TTM) was 133.8. ==> 133.8 <= 186.7 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=84.561/1526.4595
=0.05539682

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=99.101/1569.8375
=0.06312819

Immuno-Biological Laboratories Co's gearing of this year was 0.05539682. Immuno-Biological Laboratories Co's gearing of last year was 0.06312819. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=1262.12/257.824
=4.8952774

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=1165.293/252.005
=4.62408682

Immuno-Biological Laboratories Co's current ratio of this year was 4.8952774. Immuno-Biological Laboratories Co's current ratio of last year was 4.62408682. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Immuno-Biological Laboratories Co's number of shares in issue this year was 9.313. Immuno-Biological Laboratories Co's number of shares in issue last year was 9.313. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=517.293/816.701
=0.63339337

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=526.712/794.621
=0.66284682

Immuno-Biological Laboratories Co's gross margin of this year was 0.63339337. Immuno-Biological Laboratories Co's gross margin of last year was 0.66284682. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=816.701/1434.337
=0.56939269

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=794.621/1705.338
=0.465961

Immuno-Biological Laboratories Co's asset turnover of this year was 0.56939269. Immuno-Biological Laboratories Co's asset turnover of last year was 0.465961. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+1+0+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Immuno-Biological Laboratories Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Immuno-Biological Laboratories Co  (TSE:4570) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Immuno-Biological Laboratories Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Immuno-Biological Laboratories Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuno-Biological Laboratories Co Business Description

Traded in Other Exchanges
N/A
Address
1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.

Immuno-Biological Laboratories Co Headlines

No Headlines